Olubukola Ayodele: OlympiA Update – Median follow up at 6.1 years
Olubukola Ayodele, Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, shared a post on LinkedIn:
“OlympiA Update: Median follow up at 6.1 years.
- 6 yr IDFS rate 9.4% absolute benefit for olaparib HR 0.65
- in DDFS (7.8% absolute benefit) & OS (4.4% absolute benefit)
- Consistent across all subgroups
- Pregnancy data similar b/w 2 arms
- Low rate 0.4% MDS/AML in olaparib vs 0.7% in placebo
This 6.1 year follow up results continue to impress and firmly establishes olaparib as standard of care in patients with germline BRCA mutation in early stage high risk breast cancer.”
Dr. Olubukola Ayodele is a Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, specializing in breast and genitourinary malignancies, including germ cell tumors. She is also an honorary Senior Lecturer at the University of Leicester and heads the Breast Cancer Clinical Trials Unit at the Leicester Cancer Research Centre. Dr. Ayodele’s work includes numerous publications, clinical trials, and collaborative research projects on molecular drivers and biomarkers in breast cancer. She is a member of ASCO, ESMO, ACP and UKBCG.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023